{
    "title": "Reviva Pharma's schizophrenia drug succeeds in late-stage study",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12688415/Reviva-Pharmas-schizophrenia-drug-succeeds-late-stage-study.html",
    "date": "2023-10-30",
    "keywords": [
        "schizophrenia",
        "study",
        "drug",
        "brilaroxazine",
        "latestage",
        "reviva",
        "severity",
        "score",
        "scale",
        "placebo",
        "reduction",
        "treatment",
        "oct",
        "disease",
        "companys",
        "monday",
        "mental",
        "disorder",
        "distortion",
        "fright",
        "paranoia",
        "revivas",
        "sideeffect",
        "issue",
        "weight",
        "gain",
        "group",
        "outcome",
        "ceo",
        "conference",
        "call",
        "year",
        "company",
        "hypertension",
        "risperidone",
        "olanzapine",
        "quarter",
        "marketing",
        "application",
        "food",
        "administration",
        "class",
        "serotonindopamine",
        "modulator",
        "chemical",
        "brain",
        "serotonin",
        "dopamine",
        "reporting",
        "mariam",
        "sunny",
        "bengaluru",
        "editing",
        "savio",
        "dsouza"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}